Cargando…

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia

INTRODUCTION: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. METHODS: This cross-sectional study included 1592 randomly se...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Bahrani, Salma, Albarrak, Ali, Alghamdi, Othman Ali, Alghamdi, Mesfer Abdullah, Hakami, Fatimah H., Al Abaadi, Asmaa K., Alkhrashi, Sausan A., Alghamdi, Mansour Y., Almershad, Meshael M., Alenazi, Mansour Moklif, El Gezery, Mohamed Hany, Jebakumar, Arulanantham Zechariah, Al-Tawfiq, Jaffar A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310569/
https://www.ncbi.nlm.nih.gov/pubmed/34320413
http://dx.doi.org/10.1016/j.ijid.2021.07.052
_version_ 1783728787465175040
author Al Bahrani, Salma
Albarrak, Ali
Alghamdi, Othman Ali
Alghamdi, Mesfer Abdullah
Hakami, Fatimah H.
Al Abaadi, Asmaa K.
Alkhrashi, Sausan A.
Alghamdi, Mansour Y.
Almershad, Meshael M.
Alenazi, Mansour Moklif
El Gezery, Mohamed Hany
Jebakumar, Arulanantham Zechariah
Al-Tawfiq, Jaffar A.
author_facet Al Bahrani, Salma
Albarrak, Ali
Alghamdi, Othman Ali
Alghamdi, Mesfer Abdullah
Hakami, Fatimah H.
Al Abaadi, Asmaa K.
Alkhrashi, Sausan A.
Alghamdi, Mansour Y.
Almershad, Meshael M.
Alenazi, Mansour Moklif
El Gezery, Mohamed Hany
Jebakumar, Arulanantham Zechariah
Al-Tawfiq, Jaffar A.
author_sort Al Bahrani, Salma
collection PubMed
description INTRODUCTION: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. METHODS: This cross-sectional study included 1592 randomly selected vaccinees from April to May 2021. A questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose. RESULTS: Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) years and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first telephone call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and there were no hospitalizations. CONCLUSION: This study observed no major side effects of the ChAdOx1-S vaccine and no reported breakthrough infection during the observation period.
format Online
Article
Text
id pubmed-8310569
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-83105692021-07-26 Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia Al Bahrani, Salma Albarrak, Ali Alghamdi, Othman Ali Alghamdi, Mesfer Abdullah Hakami, Fatimah H. Al Abaadi, Asmaa K. Alkhrashi, Sausan A. Alghamdi, Mansour Y. Almershad, Meshael M. Alenazi, Mansour Moklif El Gezery, Mohamed Hany Jebakumar, Arulanantham Zechariah Al-Tawfiq, Jaffar A. Int J Infect Dis Article INTRODUCTION: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. METHODS: This cross-sectional study included 1592 randomly selected vaccinees from April to May 2021. A questionnaire was delivered to the vaccinees via phone calls 7 and 21 days after the first vaccine dose. RESULTS: Of the 1592 vaccinees who had the first dose, the mean age was 37.4 (± 9.6) years and 81% were males. Of all the vaccinees, 553 (34.7%) reported an adverse reaction on the first telephone call. The most common symptoms were: pain at the site of injection (485, 30.5%), musculoskeletal symptoms (438, 27.5%), skin rash (307, 19.2%), gastrointestinal symptoms (379, 23.8%) and fever (498, 31.3%). Men were more likely to report fever (76.9% vs. 23.1%; P = 0.005), skin rash (81.1% vs. 18.9%, P = 0.005) and pain at the injection site (77.3% vs. 22.7%, P < 0.0001). Post-vaccine COVID-19 infection was 0.5% and there were no hospitalizations. CONCLUSION: This study observed no major side effects of the ChAdOx1-S vaccine and no reported breakthrough infection during the observation period. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-09 2021-07-25 /pmc/articles/PMC8310569/ /pubmed/34320413 http://dx.doi.org/10.1016/j.ijid.2021.07.052 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Al Bahrani, Salma
Albarrak, Ali
Alghamdi, Othman Ali
Alghamdi, Mesfer Abdullah
Hakami, Fatimah H.
Al Abaadi, Asmaa K.
Alkhrashi, Sausan A.
Alghamdi, Mansour Y.
Almershad, Meshael M.
Alenazi, Mansour Moklif
El Gezery, Mohamed Hany
Jebakumar, Arulanantham Zechariah
Al-Tawfiq, Jaffar A.
Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
title Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
title_full Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
title_fullStr Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
title_full_unstemmed Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
title_short Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
title_sort safety and reactogenicity of the chadox1 (azd1222) covid-19 vaccine in saudi arabia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310569/
https://www.ncbi.nlm.nih.gov/pubmed/34320413
http://dx.doi.org/10.1016/j.ijid.2021.07.052
work_keys_str_mv AT albahranisalma safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT albarrakali safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT alghamdiothmanali safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT alghamdimesferabdullah safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT hakamifatimahh safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT alabaadiasmaak safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT alkhrashisausana safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT alghamdimansoury safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT almershadmeshaelm safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT alenazimansourmoklif safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT elgezerymohamedhany safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT jebakumararulananthamzechariah safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia
AT altawfiqjaffara safetyandreactogenicityofthechadox1azd1222covid19vaccineinsaudiarabia